Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
BDX's Cash to Debt is ranked lower than
86% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. BDX: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
BDX' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.55 Max: 1.03
Current: 0.17
0.04
1.03
Equity to Asset 0.30
BDX's Equity to Asset is ranked lower than
84% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BDX: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
BDX' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.47 Max: 0.62
Current: 0.3
0.27
0.62
Interest Coverage 3.69
BDX's Interest Coverage is ranked lower than
88% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. BDX: 3.69 )
Ranked among companies with meaningful Interest Coverage only.
BDX' s Interest Coverage Range Over the Past 10 Years
Min: 2.89  Med: 15.87 Max: 42.29
Current: 3.69
2.89
42.29
F-Score: 6
Z-Score: 2.80
M-Score: -2.80
WACC vs ROIC
8.19%
7.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.46
BDX's Operating margin (%) is ranked higher than
70% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. BDX: 11.46 )
Ranked among companies with meaningful Operating margin (%) only.
BDX' s Operating margin (%) Range Over the Past 10 Years
Min: 10.45  Med: 19.61 Max: 22.75
Current: 11.46
10.45
22.75
Net-margin (%) 7.81
BDX's Net-margin (%) is ranked higher than
65% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. BDX: 7.81 )
Ranked among companies with meaningful Net-margin (%) only.
BDX' s Net-margin (%) Range Over the Past 10 Years
Min: 6.76  Med: 15.56 Max: 18.49
Current: 7.81
6.76
18.49
ROE (%) 12.92
BDX's ROE (%) is ranked higher than
74% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. BDX: 12.92 )
Ranked among companies with meaningful ROE (%) only.
BDX' s ROE (%) Range Over the Past 10 Years
Min: 11.38  Med: 24.34 Max: 28.17
Current: 12.92
11.38
28.17
ROA (%) 3.74
BDX's ROA (%) is ranked higher than
61% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. BDX: 3.74 )
Ranked among companies with meaningful ROA (%) only.
BDX' s ROA (%) Range Over the Past 10 Years
Min: 3.57  Med: 11.79 Max: 14.79
Current: 3.74
3.57
14.79
ROC (Joel Greenblatt) (%) 27.36
BDX's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. BDX: 27.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 21.71  Med: 35.48 Max: 40.37
Current: 27.36
21.71
40.37
Revenue Growth (3Y)(%) 12.40
BDX's Revenue Growth (3Y)(%) is ranked higher than
83% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. BDX: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.4  Med: 9.2 Max: 12.4
Current: 12.4
4.4
12.4
EBITDA Growth (3Y)(%) 8.50
BDX's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. BDX: 8.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.6  Med: 9.1 Max: 15.7
Current: 8.5
-1.6
15.7
EPS Growth (3Y)(%) -1.30
BDX's EPS Growth (3Y)(%) is ranked lower than
65% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BDX: -1.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.2  Med: 11.4 Max: 21.9
Current: -1.3
-14.2
21.9
GuruFocus has detected 5 Warning Signs with Becton, Dickinson and Co $BDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BDX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BDX Guru Trades in Q1 2016

Paul Tudor Jones 2,300 sh (New)
Ray Dalio 10,937 sh (+115.76%)
T Rowe Price Equity Income Fund 732,099 sh (+104.61%)
First Eagle Investment 1,389,002 sh (+1.15%)
Dodge & Cox 14,930 sh (+1.01%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
Pioneer Investments 931,609 sh (-2.27%)
Vanguard Health Care Fund 2,703,387 sh (-7.97%)
Mario Gabelli 191,090 sh (-11.10%)
Mairs and Power 4,584 sh (-11.57%)
Robert Olstein 54,000 sh (-16.92%)
Jeremy Grantham 602,775 sh (-19.60%)
Jim Simons 754,966 sh (-37.47%)
Ken Fisher 1,473 sh (-47.64%)
John Hussman 25,000 sh (-50.00%)
Joel Greenblatt 19,575 sh (-75.23%)
» More
Q2 2016

BDX Guru Trades in Q2 2016

Louis Moore Bacon 2,163 sh (New)
Paul Tudor Jones 3,201 sh (+39.17%)
Jeremy Grantham 709,700 sh (+17.74%)
T Rowe Price Equity Income Fund 860,000 sh (+17.47%)
Mairs and Power 4,703 sh (+2.60%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
John Hussman 25,000 sh (unchged)
Pioneer Investments 917,916 sh (-1.47%)
Joel Greenblatt 18,713 sh (-4.40%)
Ken Fisher 1,395 sh (-5.30%)
Dodge & Cox 13,830 sh (-7.37%)
Mario Gabelli 162,864 sh (-14.77%)
Robert Olstein 46,000 sh (-14.81%)
Vanguard Health Care Fund 1,868,387 sh (-30.89%)
Ray Dalio 3,737 sh (-65.83%)
First Eagle Investment 390,407 sh (-71.89%)
Jim Simons 119,010 sh (-84.24%)
» More
Q3 2016

BDX Guru Trades in Q3 2016

Ray Dalio 5,000 sh (+33.80%)
Louis Moore Bacon 2,579 sh (+19.23%)
Mairs and Power 5,378 sh (+14.35%)
T Rowe Price Equity Income Fund 970,000 sh (+12.79%)
Jeremy Grantham 745,800 sh (+5.09%)
Tom Gayner 9,000 sh (unchged)
Dodge & Cox 13,830 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
John Hussman Sold Out
First Eagle Investment Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 1,394 sh (-0.07%)
Pioneer Investments 874,062 sh (-4.78%)
Mario Gabelli 135,909 sh (-16.55%)
Robert Olstein 36,100 sh (-21.52%)
Vanguard Health Care Fund 1,301,633 sh (-30.33%)
» More
Q4 2016

BDX Guru Trades in Q4 2016

Ken Fisher 1,760 sh (+26.26%)
T Rowe Price Equity Income Fund 984,000 sh (+1.44%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:BAX, NAS:ILMN, OTCPK:ESLOY, NYSE:BCR, OTCPK:CLPBY, OTCPK:TRUMY, NAS:XRAY, OTCPK:OCPNF, NYSE:WAT, NAS:HOLX, NYSE:MTD, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBF, NYSE:CMD, OTCPK:ANSLY » details
Traded in other countries:BOX.Germany, BDX.Switzerland, 0R19.UK,
Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Becton, Dickinson and Co was incorporated under the laws of the State of New Jersey in November 1906. The Company is a medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, general public and the pharmaceutical industry. Its operations include two business segments; BD Medical and BD Life Sciences. BD Medical produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The primary customers served by BD Medical are hospitals and clinics; physicians' office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. In addition, BD Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians' office practices; academic and government institutions; and pharmaceutical and biotechnology companies. It has manufacturing operations outside the United States, Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, the Netherlands, Pakistan, Singapore, Spain, Sweden and the United Kingdom. The Company competes in the marketplace on the basis of many factors, including price, quality, innovation, service, reputation, distribution and promotion. Its medical technology products and operations are subject to regulation by the U.S. Food and Drug Administration and various other federal and state agencies, as well as by foreign governmental agencies.

Ratios

vs
industry
vs
history
P/E(ttm) 38.55
BDX's P/E(ttm) is ranked lower than
70% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.41 vs. BDX: 38.55 )
Ranked among companies with meaningful P/E(ttm) only.
BDX' s P/E(ttm) Range Over the Past 10 Years
Min: 10.27  Med: 19.29 Max: 47.83
Current: 38.55
10.27
47.83
Forward P/E 18.32
BDX's Forward P/E is ranked higher than
78% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.27 vs. BDX: 18.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 38.55
BDX's PE(NRI) is ranked lower than
72% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.86 vs. BDX: 38.55 )
Ranked among companies with meaningful PE(NRI) only.
BDX' s PE(NRI) Range Over the Past 10 Years
Min: 13.02  Med: 20.75 Max: 47.83
Current: 38.55
13.02
47.83
Price/Owner Earnings (ttm) 25.27
BDX's Price/Owner Earnings (ttm) is ranked higher than
54% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.39 vs. BDX: 25.27 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BDX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.59  Med: 17.83 Max: 38.44
Current: 25.27
10.59
38.44
P/B 4.82
BDX's P/B is ranked lower than
70% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. BDX: 4.82 )
Ranked among companies with meaningful P/B only.
BDX' s P/B Range Over the Past 10 Years
Min: 2.96  Med: 4.11 Max: 5.6
Current: 4.82
2.96
5.6
P/S 3.01
BDX's P/S is ranked lower than
51% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. BDX: 3.01 )
Ranked among companies with meaningful P/S only.
BDX' s P/S Range Over the Past 10 Years
Min: 2  Med: 2.73 Max: 3.54
Current: 3.01
2
3.54
PFCF 20.46
BDX's PFCF is ranked higher than
72% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.12 vs. BDX: 20.46 )
Ranked among companies with meaningful PFCF only.
BDX' s PFCF Range Over the Past 10 Years
Min: 13.46  Med: 19.61 Max: 35.11
Current: 20.46
13.46
35.11
POCF 14.73
BDX's POCF is ranked higher than
61% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.81 vs. BDX: 14.73 )
Ranked among companies with meaningful POCF only.
BDX' s POCF Range Over the Past 10 Years
Min: 8.76  Med: 12.4 Max: 19.45
Current: 14.73
8.76
19.45
EV-to-EBIT 33.68
BDX's EV-to-EBIT is ranked lower than
74% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.29 vs. BDX: 33.68 )
Ranked among companies with meaningful EV-to-EBIT only.
BDX' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 14.3 Max: 40.4
Current: 33.68
9.7
40.4
EV-to-EBITDA 19.13
BDX's EV-to-EBITDA is ranked lower than
57% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.68 vs. BDX: 19.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.5  Med: 10.7 Max: 22.6
Current: 19.13
7.5
22.6
PEG 12.83
BDX's PEG is ranked lower than
95% of the 59 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. BDX: 12.83 )
Ranked among companies with meaningful PEG only.
BDX' s PEG Range Over the Past 10 Years
Min: 0.92  Med: 1.79 Max: 24.28
Current: 12.83
0.92
24.28
Shiller P/E 32.32
BDX's Shiller P/E is ranked higher than
65% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.08 vs. BDX: 32.32 )
Ranked among companies with meaningful Shiller P/E only.
BDX' s Shiller P/E Range Over the Past 10 Years
Min: 17.07  Med: 24.34 Max: 39.96
Current: 32.32
17.07
39.96
Current Ratio 1.45
BDX's Current Ratio is ranked lower than
76% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. BDX: 1.45 )
Ranked among companies with meaningful Current Ratio only.
BDX' s Current Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.21 Max: 2.76
Current: 1.45
1.23
2.76
Quick Ratio 1.06
BDX's Quick Ratio is ranked lower than
72% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BDX: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
BDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.57 Max: 2.1
Current: 1.06
0.73
2.1
Days Inventory 105.06
BDX's Days Inventory is ranked higher than
65% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. BDX: 105.06 )
Ranked among companies with meaningful Days Inventory only.
BDX' s Days Inventory Range Over the Past 10 Years
Min: 103.39  Med: 120.58 Max: 127.55
Current: 105.06
103.39
127.55
Days Sales Outstanding 47.31
BDX's Days Sales Outstanding is ranked higher than
79% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. BDX: 47.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.31  Med: 58.29 Max: 62.16
Current: 47.31
47.31
62.16
Days Payable 37.39
BDX's Days Payable is ranked lower than
67% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.06 vs. BDX: 37.39 )
Ranked among companies with meaningful Days Payable only.
BDX' s Days Payable Range Over the Past 10 Years
Min: 27.63  Med: 32.87 Max: 41.22
Current: 37.39
27.63
41.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.57
BDX's Dividend Yield is ranked higher than
60% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.29 vs. BDX: 1.57 )
Ranked among companies with meaningful Dividend Yield only.
BDX' s Dividend Yield Range Over the Past 10 Years
Min: 1.12  Med: 1.77 Max: 2.44
Current: 1.57
1.12
2.44
Dividend Payout 0.59
BDX's Dividend Payout is ranked lower than
81% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.32 vs. BDX: 0.59 )
Ranked among companies with meaningful Dividend Payout only.
BDX' s Dividend Payout Range Over the Past 10 Years
Min: 0.26  Med: 0.33 Max: 0.72
Current: 0.59
0.26
0.72
Dividend Growth (3y) 10.10
BDX's Dividend Growth (3y) is ranked lower than
52% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.90 vs. BDX: 10.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BDX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 2.6  Med: 12.5 Max: 29.1
Current: 10.1
2.6
29.1
Forward Dividend Yield 1.68
BDX's Forward Dividend Yield is ranked higher than
55% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BDX: 1.68 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.51
BDX's Yield on cost (5-Year) is ranked higher than
67% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BDX: 2.51 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BDX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.8  Med: 2.85 Max: 3.93
Current: 2.51
1.8
3.93
3-Year Average Share Buyback Ratio -3.20
BDX's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. BDX: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.2  Med: 0.8 Max: 6
Current: -3.2
-3.2
6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.79
BDX's Price/Projected FCF is ranked higher than
55% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. BDX: 1.79 )
Ranked among companies with meaningful Price/Projected FCF only.
BDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.06  Med: 1.46 Max: 3.32
Current: 1.79
1.06
3.32
Price/DCF (Earnings Based) 3.61
BDX's Price/DCF (Earnings Based) is ranked lower than
82% of the 17 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.89 vs. BDX: 3.61 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.11
BDX's Price/Median PS Value is ranked lower than
51% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.09 vs. BDX: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
BDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.7  Med: 0.93 Max: 1.27
Current: 1.11
0.7
1.27
Earnings Yield (Greenblatt) (%) 3.00
BDX's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. BDX: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 7 Max: 10.4
Current: 3
2.5
10.4
Forward Rate of Return (Yacktman) (%) 6.61
BDX's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.15 vs. BDX: 6.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BDX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5.3  Med: 14.7 Max: 19.6
Current: 6.61
5.3
19.6

More Statistics

Revenue (TTM) (Mil) $12,482
EPS (TTM) $ 4.50
Beta0.99
Short Percentage of Float1.58%
52-Week Range $129.50 - 181.76
Shares Outstanding (Mil)231.23

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 12,111 12,718 13,150
EPS ($) 9.48 10.44 11.10
EPS w/o NRI ($) 9.48 10.44 11.10
EPS Growth Rate
(3Y to 5Y Estimate)
9.55%
Dividends Per Share ($) 2.80 3.02 3.51
» More Articles for BDX

Headlines

Articles On GuruFocus.com
5 Stocks to Avoid - January 2017 Jan 14 2017 
Top 7 Dividend Health Care Stocks Jan 05 2017 
The 10 Best Dividend Aristocrats for 2017 and Beyond Dec 23 2016 
Becton Dickinson Lifts Dividend by 11% Nov 30 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
Dividend Aristocrats in Focus Part 26: Becton, Dickinson and Co. Nov 02 2016 
Numerous Companies Reach Yearly Highs Oct 03 2016 
The 10 Best Dividend Aristocrats Aug 15 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Mawer Investment Newsletter 2nd Quarter 2016 Jul 15 2016 

More From Other Websites
Becton, Dickinson Commercially Launches Precise WTA Kits Jan 18 2017
BD Launches Reagents to Simplify Single Cell Research Jan 17 2017
Becton, Dickinson & Co. – Value Analysis (NYSE:BDX) : January 11, 2017 Jan 11 2017
Post Earnings Coverage as AngioDynamics Adjusted EPS Soared 36% Jan 11 2017
BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call Jan 11 2017
Becton, Dickinson & Co. breached its 50 day moving average in a Bullish Manner : BDX-US : January... Jan 10 2017
BD to Present at the 35th Annual J. P. Morgan Healthcare Conference Jan 09 2017
Top 7 Dividend Health Care Stocks Jan 05 2017
How Do Wall Street Analysts View Becton Dickinson? Jan 05 2017
Becton Dickinson downgraded by Raymond James Jan 05 2017
A Look at Becton Dickinson’s Recent Stock Performance Jan 04 2017
Inside Becton Dickinson’s Financial Guidance for 2017 Jan 04 2017
10 Great All-Weather Stocks Jan 04 2017
BD’s Latest Dividend Payment and Capital Allocation Strategy Jan 04 2017
A Look at BDX’s Recent Product Launches Jan 03 2017
Analyzing the BD Medical Segment’s Product Pipeline Jan 03 2017
BD’s Medical Segment Performance and Growth Strategy Jan 03 2017
BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth Jan 02 2017
BD Lifesciences’s Performance and Core Focus Areas Jan 02 2017
Becton Dickinson’s Long-Term Growth Profile and Expectations Jan 02 2017
Unusual activity: BDX & JBLU Dec 29 2016
The 10 Best Dividend Aristocrats for 2017 and Beyond Dec 23 2016
Current report no 73 / 2016 Dec 01 2016
Current report no 72 / 2016 Dec 01 2016
Current report no 74 / 2016 Dec 01 2016
Current report no 75 / 2016 Dec 01 2016
BD to Offer Euro-denominated Senior Unsecured Notes Dec 01 2016
BD Announces Adoption of Windows 10 'Internet of Things' for the Pyxis™ ES System Dec 01 2016
Budimex to reconstruct Provincial Hospital in Toruń Nov 23 2016
Current report no 71 / 2016 Nov 23 2016
The first project of the Budimex Group in the gaseous fuels market Nov 22 2016
BD Board Increases Dividend Nov 21 2016
BD Announces 2016 Analyst Day And Webcast Nov 14 2016
Budimex adopts the Diversity Charter Nov 10 2016
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin Nov 08 2016
BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance Nov 03 2016
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal... Oct 31 2016
Current report no 70 / 2016 Oct 28 2016
Design works and construction of a ring road in Warsaw. Oct 27 2016
Executive Commentary of Chairman of the Management Board on selected financial data for 3Q 2016 Oct 27 2016
Current report no 69 / 2016 Oct 24 2016
Current report no 68 / 2016 Oct 17 2016
New effort launched to connect U.S. businesses with clean energy Feb 02 2015
Becton Dickinson to buy CareFusion for $12 billion in cash, stock Oct 05 2014
Becton Dickinson to buy CareFusion for $12 billion in cash, stock Oct 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)